Evidence map›Paper›PMID 35139223›Full record

ArticleJournal of the Pediatric Infectious Diseases Society2022

"An Extra Variable to Consider"-Vaccine-Induced Seropositivity and Adolescent HIV Vaccine Clinical Trials.

Omolayo Fatola, Amy Corneli, Brian Perry, Emily Hanlen-Rosado, Adora Nsonwu, Evangelia P Constantine, Amelia B Thompson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Pediatric Infectious Diseases Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Omolayo FatolaIndiana University School of Medicine, Indianapolis, Indiana, USA.
Amy CorneliDepartment of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA.
Brian PerryDepartment of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA.
Emily Hanlen-RosadoDepartment of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA.
Adora NsonwuDepartment of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA.
Evangelia P ConstantineDartmouth College, Hanover, New Hampshire, USA.
Amelia B ThompsonDuke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
NIAID NIH HHS P30 AI064518NIAID NIH HHS UM1 AI068614NIH HHS 5P30 AI064518
6 · The paper itself

Abstract

Our study explores the understanding of vaccine-induced seropositivity (VISP) and its potential impact on US adolescents' and caregivers' willingness to participate in adolescent HIV vaccine clinical trials. Findings from in-depth interviews suggest that addressing concerns about VISP will be essential for future pediatric HIV vaccine trials in the United States.

Indexed as

AIDS VaccinesHIV InfectionsAdolescentChildHealth Knowledge, Attitudes, PracticeHumansUnited StatesAIDS VaccinesadolescentHIVpreventionvaccineVISP

Identifiers

PMID35139223
PMCPMC9155599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.